-
Je něco špatně v tomto záznamu ?
Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor
Z. Pavelek, O. Soucek, J. Krejsek, I. Sejkorova, O. Vysata, B. Klimová, F. Angelucci, P. Stourac, M. Valis, M. Peterka, L. Sobisek, M. Novotny
Jazyk angličtina Země Egypt
Typ dokumentu pozorovací studie, časopisecké články
NLK
Directory of Open Access Journals
od 1990
Free Medical Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014
ProQuest Central
od 2008-01-01
Open Access Digital Library
od 1990-01-01
Open Access Digital Library
od 2014-01-01
Open Access Digital Library
od 2014-01-08
Medline Complete (EBSCOhost)
od 2014-01-01
Health & Medicine (ProQuest)
od 2008-01-01
Wiley-Blackwell Open Access Titles
od 1990
ROAD: Directory of Open Access Scholarly Resources
od 2014
PubMed
37064009
DOI
10.1155/2023/4653627
Knihovny.cz E-zdroje
- MeSH
- ELISA MeSH
- fingolimod hydrochlorid terapeutické užití MeSH
- imunitní systém MeSH
- interferon gama MeSH
- lidé MeSH
- relabující-remitující roztroušená skleróza * MeSH
- roztroušená skleróza * diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: The QuantiFERON®-Monitor (QFM) is an assay that measures interferon-γ production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-γ levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. METHODS: This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-γ was measured using the ELISA kit for the QFM and data were obtained in IU/ml. RESULTS: The results showed that controls had nearly 2-fold higher levels of IFN-γ (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. CONCLUSIONS: Results showed that controls had higher levels of IFN-γ production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-γ. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010467
- 003
- CZ-PrNML
- 005
- 20230801132438.0
- 007
- ta
- 008
- 230718s2023 ua f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2023/4653627 $2 doi
- 035 __
- $a (PubMed)37064009
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ua
- 100 1_
- $a Pavelek, Zbysek $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000217728781
- 245 10
- $a Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor / $c Z. Pavelek, O. Soucek, J. Krejsek, I. Sejkorova, O. Vysata, B. Klimová, F. Angelucci, P. Stourac, M. Valis, M. Peterka, L. Sobisek, M. Novotny
- 520 9_
- $a BACKGROUND: The QuantiFERON®-Monitor (QFM) is an assay that measures interferon-γ production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-γ levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. METHODS: This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-γ was measured using the ELISA kit for the QFM and data were obtained in IU/ml. RESULTS: The results showed that controls had nearly 2-fold higher levels of IFN-γ (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. CONCLUSIONS: Results showed that controls had higher levels of IFN-γ production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-γ. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a roztroušená skleróza $x diagnóza $x farmakoterapie $7 D009103
- 650 _2
- $a fingolimod hydrochlorid $x terapeutické užití $7 D000068876
- 650 _2
- $a interferon gama $7 D007371
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a imunitní systém $7 D007107
- 650 12
- $a relabující-remitující roztroušená skleróza $7 D020529
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Soucek, Ondrej $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Krejsek, Jan $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Czech Republic $1 https://orcid.org/0000000327786800 $7 nlk19990073429
- 700 1_
- $a Sejkorova, Ilona $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Czech Republic
- 700 1_
- $a Vysata, Oldrich $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 700 1_
- $a Klimová, Blanka $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000180009766 $7 jo2004259816
- 700 1_
- $a Angelucci, Francesco $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 700 1_
- $a Stourac, Pavel $u Department of Neurology, University Hospital and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Valis, Martin $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
- 700 1_
- $a Peterka, Marek $u Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzeň, Czech Republic
- 700 1_
- $a Sobisek, Lukáš $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000180712005 $7 xx0238269
- 700 1_
- $a Novotny, Michal $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000315654181
- 773 0_
- $w MED00186351 $t Journal of immunology research $x 2314-7156 $g Roč. 2023, č. - (2023), s. 4653627
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37064009 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132435 $b ABA008
- 999 __
- $a ok $b bmc $g 1963095 $s 1196732
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 2023 $c - $d 4653627 $e 20230407 $i 2314-7156 $m Journal of immunology research $n J. immunol. res. $x MED00186351
- LZP __
- $a Pubmed-20230718